Increased omega-3 fatty acid composition of human skeletal muscle phospholipids is linked to improved skeletal muscle strength and growth in women and men. However, what is unknown is if biological sex influences skeletal muscle phospholipid composition in response to omega-3 fatty acid supplementation. Moreover, whilst time course changes in skeletal muscle phospholipid composition with omega-3 fatty acid intake have been established, no study has characterized a washout of omega-3 fatty acids from skeletal muscle phospholipids following cessation of omega-3 fatty acid intake. Thus, the aim of the present investigation is to establish a time course change and washout of omega-3 fatty acids from skeletal muscle phospholipids in response to omega-3 fatty acid intake. The investigators also aim to establish if this washout is impacted by biological sex.
Previous work has shown that supplementing with omega-3 fatty acids leads to increased omega-3 fatty acid composition of skeletal muscle phospholipids. This increase in skeletal muscle omega-3 fatty acid phospholipid composition following omega-3 fatty acid intake is linked to potentiated rates of skeletal muscle protein synthesis in response to amino acid and insulin infusion in older and younger women and men. Supplementation with omega-3 fatty acids is also known to enhance skeletal muscle strength and size in older adults. The exact biological mechanisms responsible for the anabolic influence of omega-3 fatty acid are unknown. However, there is emerging data that acid (EPA) and docosahexaenoic acid (DHA) play an active role. Indeed, there is now a growing body of evidence in cells, preclinical models, and humans that these key omega-3 fatty acids are primarily responsible for the observed anabolic impact of omega-3 fatty acids supplement intake towards skeletal muscle. Whilst there is a growing body of literature supporting the anabolic potential of EPA and DHA in skeletal muscle, few studies have examined how biological sex influences EPA and DHA incorporation into skeletal muscle. Indeed, it has been purported that women EPA to DHA more efficiently in blood erythrocytes compared to men. To the investigators knowledge, no study examined how biological sex impacts changes in skeletal muscle phospholipid profiles in response to EPA and DHA intake. Moreover, no study has established a time course washout of EPA and DHA from skeletal muscle phospholipids in response to the cessation of EPA and DHA intake. The lack of data regarding EPA and DHA washout from skeletal muscle in response to EPA and DHA intake limits the ability to execute within subject cross over trials, which is important given that within-subject cross over trials possess more statistical power than parallel arm trials. Thus, establishing a washout of EPA and DHA from skeletal muscle phospholipids in response to EPA and DHA intake would provide important information for the design of future trials in this field.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
29
Participants in this group will receive 5g fish oil with high EPA and DHA content per day
School of Kinesiology and Health Studies
Kingston, Ontario, Canada
Changes in skeletal muscle EPA and DHA content
Skeletal muscle phospholipid composition will be assessed at all time points by means of gas chromatography
Time frame: At 0, 6, 8, 16, 20, and 22 weeks.
Changes in the expression of mitochondrial related proteins
Mitochondrial proteins involved in oxidative phosphorylation (e.g. ANT1) will be assessed by means of western blotting at all time points.
Time frame: 0, 6, 8, 16, 20, and 22 weeks.
Changes in erythrocyte EPA and DHA content
Erythrocyte phospholipid composition will be assessed at all time points by means of gas chromatography
Time frame: 0, 6, 8, 16, 20, and 22 weeks.
Changes in the expression of translational factors related to skeletal muscle protein synthesis
Translational factors involved in skeletal muscle protein synthesis (e.g. p70S6K1) will be assessed by means of western blotting at all time points.
Time frame: 0, 6, 8, 16, 20, and 22 weeks.
Changes in circulating glucose concentrations
Glucose concentrations will be assessed by ELISA at all time points.
Time frame: 0, 6, 8, 16, 20, and 22 weeks.
Changes in circulating insulin concentrations
Insulin concentrations will be assessed by ELISA at all time points.
Time frame: 0, 6, 8, 16, 20, and 22 weeks.
Changes in circulating TNFa concentrations
TNFa concentrations will be assessed by ELISA at all time points.
Time frame: 0, 6, 8, 16, 20, and 22 weeks.
Changes in circulating CRP concentrations
CRP concentrations will be assessed by ELISA at all time points.
Time frame: 0, 6, 8, 16, 20, and 22 weeks.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.